1. Regulated cell death joins in atherosclerotic plaque silent progression.
- Author
-
Uyy E, Suica VI, Boteanu RM, Cerveanu-Hogas A, Ivan L, Hansen R, and Antohe F
- Subjects
- Alarmins blood, Animals, Aorta metabolism, Aorta pathology, Apoptosis genetics, Atherosclerosis blood, Atherosclerosis pathology, Diet, High-Fat adverse effects, Disease Models, Animal, Disease Progression, Gene Expression Regulation genetics, Humans, Lipid Peroxidation genetics, Lipids genetics, Mass Spectrometry, Oxidative Stress genetics, Plaque, Atherosclerotic blood, Plaque, Atherosclerotic pathology, Proteome metabolism, Rabbits, Alarmins genetics, Atherosclerosis genetics, Lipids blood, Plaque, Atherosclerotic genetics
- Abstract
Non-apoptotic regulated cell death (ferroptosis and necroptosis) leads to the release of damage-associated molecular patterns (DAMPs), which initiate and perpetuate a non-infectious inflammatory response. We hypothesize that DAMPs and non-apoptotic regulated cell death are critical players of atherosclerotic plaque progression with inadequate response to lipid-lowering treatment. We aimed to uncover the silent mechanisms that govern the existing residual risk of cardiovascular-related mortality in experimental atherosclerosis. Proteomic and genomic approaches were applied on the ascending aorta of hyperlipidemic rabbits and controls with and without lipid-lowering treatment. The hyperlipidemic animals, which presented numerous heterogeneous atherosclerotic lesions, exhibited high concentrations of serum lipids and increased lipid peroxidation oxidative stress markers. The analyses revealed the significant upregulation of DAMPs and proteins implicated in ferroptosis and necroptosis by hyperlipidemia. Some of them did not respond to lipid-lowering treatment. Dysregulation of five proteins involved in non-apoptotic regulated cell death proteins (VDAC1, VDAC3, FTL, TF and PCBP1) and nine associated DAMPs (HSP90AA1, HSP90AB1, ANXA1, LGALS3, HSP90B1, S100A11, FN, CALR, H3-3A) was not corrected by the treatment. These proteins could play a key role in the atherosclerotic silent evolution and may possess an unexplored therapeutic potential. Mass spectrometry data are available via ProteomeXchange with identifier PXD026379., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF